





Chronic Leukemia's

Team leaders : Abdulrahman Alageel, Ebtesam Almutairi.
Done by :Khalid aldosari, Saif ALMeshari,
sultan al nasser.

-  Impotent
-  Notes
-  Doctor's slides

Chronic Leukemia's

- Heterogeneous group of hematopoietic neoplasms
- **Uncontrolled proliferation and decreased apoptotic activity with variable degrees of differentiation**^[1]
- Composed of relatively **mature**^[2] cells
- Indolent. (If untreated, the course is in months or years)
- Occurs mainly in adults.



	Acute	Chronic ^[4]
Lymphoid	ALL	LPN(CLL)
Myeloid	AML	MPN/MDS (CML)
Mixed	Acute Biphenotypic	
Non	Acute Undifferentiated	




Table 1. Classification of Myeloid Neoplasms According to the 2008 World Health Organization Classification Scheme

- 1. Myeloproliferative neoplasms (MPN)**
 - 1.1. Chronic myelogenous leukemia, *BCR-ABL1*-positive (CML)
 - 1.2. Polycythemia vera (PV)^[5]
 - 1.3. Essential thrombocythemia (ET)^[6]
 - 1.4. Primary myelofibrosis (PMF)
 - 1.5. Chronic neutrophilic leukemia (CNL)
 - 1.6. Chronic eosinophilic leukemia, not otherwise specified (CEL-NOS) *Chronic Basophilic leukemia will release histamine*
 - 1.7. Mast cell disease (MCD)
 - 1.8. MPN, unclassifiable
- 2. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of *PDGFRA*, *PDGFRB*, and *FGFR1***
- 3. MDS/MPN^[7]**
 - 3.1. Chronic myelomonocytic leukemia (CMML) *In adults*
 - 3.2. Juvenile myelomonocytic leukemia (JMML) *In children*
 - 3.3. Atypical chronic myeloid leukemia, *BCR-ABL*-negative (aCML) *Same feature of CML but (-) genetics.*
 - 3.4. MDS/MPN, unclassifiable
- 4. Myelodysplastic syndromes (MDS)** *في تشوهه morphology(dysplastic)*
- 5. Acute myeloid leukemia (AML)**

[1] you will see mature cells: neutrophils, basophils, RBC, platelets.

[2] chronic -> mature cells and take months or years to appear [silent], acute -> immature and take hours.

[3] No block of differentiation + mutation here will affect stem cell but it will be mature unlike in acute.

[4] Unlike acute there is no ambiguous.

[5] malignancy affecting erythroid precursor will lead to increase number of RBCs, will present with high CBC especially **RBCs, HB** → **differentiation**.

[6] high platelet count mutation in megakaryocyte → it may increase up to 2 million platelet

Sometime the patient may come with bleeding because of the platelet not functioning and sometime they may come with DVT

[7] MPN: monocytosis or leukosytosis or neutrophilia, MDS: Cytopenia, anemia, thrombocytopenia.

[8] In NTs if you see myeloperoxidase absent this is part of malignancy.

Myeloproliferative Neoplasms

- Malignant proliferation of myeloid cells (maturing cells) which are mainly **granulocytes**, in blood and bone marrow.
- Occur mainly in **adults**
- Slow onset and long course.
-


CML and MPN are almost the same
But MPN اشمل it is include CML and polycythemia
All one categorise

Myeloproliferative Neoplasms features :

- **Cytoses** ^[1]
- **Organomegaly (mainly splenomegaly)** ^[2]
- **High uric acid** ^[3]
- **Hypercellular** (mature cell not blast) **bone marrow**
- **Progression to acute leukaemia (mainly AML)**

Chronic Myeloid Leukemia (CML) ^[4]

- Stem cell MPN. ^[5]
- Predominant proliferation of **granulocytic** cells.
- Consistently associated with the **BCR-ABL1** (protein) fusion gene located in the **Philadelphia (Ph) chromosome** which results from **t(9;22)** . ^[6]



myeloblast

promyelocyte

myelocyte

metamyelocyte

band

neutrophil ^[7]

MATURATION

[1] (leukocytosis, thrombocytosis, erythrocytosis) At least one of them.

[2] It will try to take all cells to decrease the viscosity of the blood to prevent DVT. Sometime it will start to synthesis of cell.

[3] (because of increase destruction of cells)

[4] Before the diagnosis is based on morphology, leukocytosis and splenomegaly. Now it's based on Genetic.



The patient come with leukocytosis and the prognosis 95% death , now it is 95% cure after we know the gene and the drug.

[5] you will have many NTs, myelocytes


[6] No CML without BCR-ABL1

[7] if you see CBC you find myelocyte and neutrophil increase most likely he has CML


Pathogenesis of CML




Source: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J: Harrison's Principles of Internal Medicine, 18th Edition; www.accessmedicine.com Copyright © The McGraw-Hill Companies, Inc. All rights reserved.



Autonomous proliferation



Will go to nucleus and cause proliferation



When chromosomes 9 and 22 exchange portions of their genetic material, this translocation results in the formation of der(9), an elongated chromosome 9, and the Ph chromosome, which contains the hybrid BCR-ABL gene.

Clinical Presentation

- Asymptomatic presentation(20-40%):
- Routine CBC : marked **leukocytosis**
- Common symptoms : Fatigue , weight loss or night sweating
- Abdominal discomfort due to splenomegaly
- **Splenomegaly (Massive)**^[1] →



[1] massive exceeding the umbilicus
3 causes: 1- CML
2- lieshmenia
3- primary myelofibrosis



Main Differential Diagnosis

1- **Chronic myelomonocytic leukemia** (monocytosis ,**BCR-ABL -ve**) .

2-Leukemoid reaction: Leukocytosis due to physiological response to stress or infection or autoimmune disease.

	CML	Leukaemoid
Age	Adult	Any age
WBC count	High	High but <100,000
Differential	Mainly myelocytes and <u>segmented</u>	Mainly <u>Bands</u>
Morphology	Hypogranular	Toxic
Splenomegaly	+	-/+
NAP score	<u>Low</u>	<u>High</u>
BCR/ABL	<u>+ve</u>	<u>-ve</u>
Onset	Chronic	Acute


Neutrophil Alkaline Phosphatase (NAP)score :
 Cytochemical stain that estimate the amount of alkaline phosphatase enzyme in neutrophils .



CML Phases


Chronic phase

- **Leukocytosis** ($12-1000 \times 10^9/L$)
- **Mainly neutrophils & myelocytes**
- **Blasts $\leq 10\%$, Basophils $\leq 20\%$**
- **Stable course (years)**




Accelerated phase^[1]

- **Increasing counts**
- **10-19% blasts (basophils $\geq 20\%$)**
- **Unstable course (months)**




Blastic phase

- **$\geq 20\%$ blasts = Acute Leukemia^[2]**
- **80% AML & 20% ALL**
- **(course: Weeks)**



CML Treatment

- Targeted therapy (tyrosine kinase inhibitors like Imatinib)^[3]
- Excellent response (5y overall survival $\geq 90\%$)^[4]
- If no response ; stem cell transplantation



[1] you have to give them chemotherapy ل مايرودون phase3

[2] AL you should give them chemotherapy

[3] It's expensive and it has little side effect bitter than paracetamol.

[4] 10% have mutation in BCR-ABL.

Myelodysplastic Syndromes MDS^[1]

Group of myeloid neoplasms characterized by:

1. Peripheral **cytopenia** (Low HB ± Low WBC & Low PLT)^[2]
2. **Dysplasia** (abnormal morphology)
3. **Ineffective hematopoiesis** (hypercellular marrow)^[3]
4. Progression to AML (pre leukemic disease)
5. **Enhanced apoptosis**

Many subtypes according to:



1-Blast count (MDS related to AML)

2-Degree of **dysplasia** ^[4]


3-Genetics

- **Variable genetic abnormalities mainly -5, -7**
- **Treatment : supportive +/- chemotherapy**^[5]

-5: monosomy, good prognosis, more in female
-7: monosomy, bad prognosis.



Blood: Pancytopenia with dysplasia



BM: Hypercellular with dysplasia

↑ Proliferation



↑ Apoptosis



Ineffective Hematopoiesis

[1] production of abnormal morphological cells.

[2] In MPN will have peripheral cytosis.

[3] Because of ineffective hematopoiesis → BM produce cell but not functioning will die in peripheral blood that is why he will have 1- cytopenia 2- hypercellular BM

[4] may come with pancytopenia affect WBCs, RBCs, Platelet or may one of them (unilinear, unilineage)

[5] we give him transfusion RBCs or Antibody or platelet depending on the problem

Chronic Myelomonocytic Leukemia (CMML)^[1]

❖ Clonal Hematopoietic malignancy characterized by proliferation **of both monocytes and neutrophils**.^[2]

❖ MDS/MPN disease:

* **Features of MDS (dysplasia& enhanced apoptosis)**


* **Features of MPN (marked proliferation)**

❖ **Philadelphia chromosome must be negative**.^[3]

❖ Blast must be less than 20%.

❖ Aggressive course (survival rate around 2.5 y)

❖ Treatment : Chemotherapy ±SCT^[4]



MPN vs. MDS vs. MPN/MDS

MPN

MPN/MDS

MDS

Cytosis

Cytopenia

[1] will present with very severe anemia and cytosis

[2] reduction of platelet and RBC

[3] positive = CML

[4] stem cell transplantation